Loading...
Market
Will major insurance providers cover Guardant Health's colon cancer test within 6 months post-FDA approval?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Insurance provider announcements or reliable healthcare news
Story
Independent FDA Panel Recommends Approval of Guardant Health's Blood-Based Colon Cancer Test
May 23, 2024, 06:31 PM
Advisers to the U.S. Food and Drug Administration (FDA) have recommended the approval of Guardant Health's blood-based test for detecting colorectal cancer. If approved, this will be the first blood screening test for colorectal cancer that meets the requirements for Medicare reimbursement. The recommendation by an independent panel marks a significant step towards FDA approval in the U.S., potentially improving early detection and treatment of colon cancer.
View original story
Similar markets
Yes • 50%
No • 50%
No expansion • 25%
Expansion to 1-3 countries • 25%
Expansion to 4-6 countries • 25%
Expansion to more than 6 countries • 25%
EU • 33%
Asia • 33%
South America • 33%
Increase by less than 10% • 25%
Increase by 10% to 20% • 25%
Increase by 20% to 30% • 25%
Increase by more than 30% • 25%